Two health-economic studies published in PubMed provide the first detailed projections of what population-scale multi-cancer early detection screening would demand from healthcare infrastructure and what it would cost payers, arriving as GRAIL contends with its Galleri test's primary endpoint miss in the NHS trial last week.
A modeling study estimated that MCED screening in England at 70% uptake among approximately 13 million people aged 50–79 would generate 13,730 additional colonoscopies annually—a 2.09% increase—and 62,320 additional CT scans per year, a 0.76% increase in national demand. Per million people screened, that translates to 1,040 colonoscopies and 4,720 CT scans. The figures provide the first concrete resource-planning benchmarks for health systems evaluating MCED adoption and highlight downstream infrastructure demands not addressed in GRAIL's commercial messaging.
A separate cost-effectiveness analysis modeled MCED screening at a base test price of $949 and a 25% discounted price of $712. The study found an incremental cost-effectiveness ratio between $50,000 and $100,000 per quality-adjusted life year from commercial insurance and Medicare perspectives, assuming MCED cost growth did not outpace cancer management spending. The model projected cost neutrality within 5–10 years when cancer management costs grew significantly faster than MCED test costs, but failed to reach cost neutrality within 30 years when MCED cost growth exceeded cancer management cost growth.
Both studies rely on modeled assumptions rather than observed trial outcomes. Neither incorporates unpublished signal-of-origin performance data from the NHS-Galleri trial. The $50,000–$100,000 per QALY range falls within thresholds commonly cited by US payers, but the sensitivity to pricing trajectory complicates GRAIL's reimbursement negotiations. The dossier does not specify funding sources for either analysis.
The studies land as GRAIL faces multiple headwinds. Days before the NHS trial readout, the company announced integration of Galleri into Epic's electronic health record platform, gaining access to more than 300 million patient records—a distribution play now carrying less weight without stronger clinical evidence. US FTC and EU antitrust regulators ordered Illumina to divest GRAIL, finalizing a two-year regulatory saga. Illumina itself cut full-year revenue guidance and announced $100 million in cost reductions after China banned and subsequently lifted a ban on importing its sequencers, though the company's CEO expressed hope for a long-term solution.
Full data from the NHS-Galleri trial remain the next catalyst. GRAIL's ability to secure broad reimbursement—and sustain pricing near the $712–$949 range modeled—will depend on whether secondary endpoints or subgroup analyses salvage a clinical narrative the primary endpoint did not support.